Selected article for: "death risk and glucocorticoid therapy"
Author: Shuya Lu; Qi Zhou; Liping Huang; Qianling Shi; Siya Zhao; Zijun Wang; Weiguo Li; Yuyi Tang; Yanfang Ma; Xufei Luo; Toshio Fukuoka; Hyeong Sik Ahn; Myeong Soo Lee; Zhengxiu Luo; Enmei Liu; Yaolong Chen; Chenyan Zhou; Donghong Peng
Title: Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis
  • Document date: 2020_4_22
    • ID: 935r7w01_52
    Snippet: Systemic glucocorticoids are highly effective anti-inflammatory drugs, but their use against SARS-CoV-2 infection remains controversial. A case series of children with COVID-19 in Hubei reported that systematic glucocorticoids (dose 2 mg/kg) were given to both two included critical cases in combination with invasive mechanical ventilation and intravenous immunoglobulin. In both children, the symptoms on admission were alleviated, although in one .....
    Document: Systemic glucocorticoids are highly effective anti-inflammatory drugs, but their use against SARS-CoV-2 infection remains controversial. A case series of children with COVID-19 in Hubei reported that systematic glucocorticoids (dose 2 mg/kg) were given to both two included critical cases in combination with invasive mechanical ventilation and intravenous immunoglobulin. In both children, the symptoms on admission were alleviated, although in one of them only partly (52). A recent cohort study from JAMA Internal Medicine reported that among COVID-19 patients with ARDS, treatment with methylprednisolone decreased the risk of death (39). Our results are compared with published systematic reviews of glucocorticoid therapy for severe pneumonia. A recent rapid review of COVID-19 treatment showed controversial evidence on the use of corticosteroids, and could not give any suggestion on the use of corticosteroids due to the lack of quantitative synthesis (53). A systematic review covering in vitro studies on SARS, SARS in humans and other diseases such as ARDS, found that 25 of the 29 included studies were inconclusive, and the remaining four found glucocorticoids harmful (54). A recent systematic review of influenza All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • admission symptom and ARDS patient: 1
    • admission symptom and case series: 1, 2, 3, 4, 5, 6
    • admission symptom and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission symptom and glucocorticoid therapy: 1
    • admission symptom and include study: 1
    • anti inflammatory drug and case series: 1, 2
    • anti inflammatory drug and cohort study: 1, 2, 3
    • anti inflammatory drug and controversial evidence: 1
    • ARDS disease and case series: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • ARDS disease and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • ARDS patient and case series: 1, 2, 3, 4, 5
    • ARDS patient and cohort study: 1, 2, 3, 4, 5, 6, 7, 8
    • ARDS patient and critical case: 1, 2, 3, 4, 5, 6, 7
    • case series and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • case series and controversial evidence: 1, 2
    • case series and controversial remain: 1
    • case series and critical case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • case series and glucocorticoid therapy: 1, 2, 3, 4, 5, 6, 7, 8
    • case series and include study: 1, 2, 3, 4, 5, 6